Thyrocare TechnologiesNSE:THYROCARE -3.71%87 Altman Z-Score is 33.28 as of Jul. 12, 2026, which is 32% above its 10-year median of 25.21. GuruFocus rates NSE:THYROCARE with a GF Score™ of 87/100 and a GF Value™ of ₹395.01 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, Thyrocare Technologies ranks better than 99.02% on this metric.
The Altman Z-Score is a model designed to predict the likelihood of a company going bankrupt within the next two years. Created by American finance professor Edward Altman in 1968, the model is specifically designed for publicly traded manufacturing companies with assets greater than $1 million.
Good Sign:
Altman Z-score of 33.28 is strong.
Thyrocare Technologies has a Altman Z-Score of 33.28, indicating it is in Safe Zones. This implies the Altman Z-Score is strong.
The zones of discrimination were as such:
When Altman Z-Score <= 1.8, it is in Distress Zones.
When Altman Z-Score >= 3, it is in Safe Zones.
When Altman Z-Score is between 1.8 and 3, it is in Grey Zones.
The historical rank and industry rank for Thyrocare Technologies's Altman Z-Score or its related term are showing as below:
NSE:THYROCARE'
s Altman Z-Score Range Over the Past 10 Years
Min: 16.42 Med: 25.21 Max: 79.35
Current: 33.28
During the past 13 years, Thyrocare Technologies's highest Altman Z-Score was 79.35. The lowest was 16.42. And the median was 25.21.
X1: The Working Capital/Total Assets (WC/TA) ratio is a measure of the net liquid assets of the firm relative to the total capitalization. Working capital is defined as the difference between current assets and current liabilities. Ordinarily, a firm experiencing consistent operating losses will have shrinking current assets in relation to total assets. Altman found this one proved to be the most valuable liquidity ratio comparing with the current ratio and the quick ratio. This is however the least significant of the five factors.
X2: Retained Earnings/Total Assets: the RE/TA ratio measures the leverage of a firm. Retained earnings is the account which reports the total amount of reinvested earnings and/or losses of a firm over its entire life. Those firms with high RE, relative to TA, have financed their assets through retention of profits and have not utilized as much debt.
X3, Earnings Before Interest and Taxes/Total Assets (EBIT/TA): This ratio is a measure of the true productivity of the firm's assets, independent of any tax or leverage factors. Since a firm's ultimate existence is based on the earning power of its assets, this ratio appears to be particularly appropriate for studies dealing with corporate failure. This ratio continually outperforms other profitability measures, including cash flow.
X4, Market Value of Equity/Book Value of Total Liabilities (MVE/TL): The measure shows how much the firm's assets can decline in value (measured by market value of equity plus debt) before the liabilities exceed the assets and the firm becomes insolvent.
X5, Revenue/Total Assets (S/TA): The capital-turnover ratio is a standard financial ratio illustrating the sales generating ability of the firm's assets.
Altman Z-Score does not apply to financial companies.
Thyrocare Technologies Altman Z-Score Related Terms
Thyrocare Technologies Altman Z-Score Historical Data
* Premium members only.
The historical data trend for Thyrocare Technologies's Altman Z-Score can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:THYROCARE vs TMO, DHR, IDXX: Altman Z-Score Comparison
For the Diagnostics & Research subindustry, Thyrocare Technologies's Altman Z-Score, along with its competitors' market caps and Altman Z-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Thyrocare Technologies Altman Z-Score vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Thyrocare Technologies's Altman Z-Score distribution charts can be found below:
* The bar in red indicates where Thyrocare Technologies's Altman Z-Score falls into.
Altman Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency. GuruFocus does not calculate Altman Z-Score when X4 or X5 value is 0.
Thyrocare Technologies (NSE:THYROCARE) has a Altman Z-Score of 33.28 as of Jul. 12, 2026. The Altman Z-score measures a company's bankruptcy risk. View historical data on Thyrocare Technologies and its competitors. This is 32% above median its historical median of 25.21. Over the past decade, Thyrocare Technologies' Altman Z-Score has ranged from 16.42 to 79.35. According to the industry distribution chart, Thyrocare Technologies ranks #2 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 1%.
Is Thyrocare Technologies' Altman Z-Score too high?
Thyrocare Technologies' current Altman Z-Score of 33.28 is 32% above median its 10-year median of 25.21. Over the past 10 years, this metric has ranged from a low of 16.42 to a high of 79.35. The Medical Diagnostics & Research industry median Altman Z-Score is 2.40. Thyrocare Technologies' value of 33.28 is 1286.7% above this industry median. Based on the distribution chart, Thyrocare Technologies ranks #2 out of 204 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Thyrocare Technologies has a GF Score™ of 87/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Thyrocare Technologies' Altman Z-Score compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Thyrocare Technologies ranks #2 out of 204 companies for Altman Z-Score. This places Thyrocare Technologies in the top 1% of its industry — outperforming the majority of peers. The industry median Altman Z-Score is 2.40. Thyrocare Technologies' value of 33.28 is 1286.7% above this benchmark. Historically, Thyrocare Technologies' own Altman Z-Score has ranged from 16.42 to 79.35 over the past decade. While the company's 10-year median is 25.21 vs. the industry median of 2.40, Thyrocare Technologies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Altman Z-Score for a Medical Diagnostics & Research company?
The median Altman Z-Score among Medical Diagnostics & Research companies is 2.40, based on 204 companies in the industry. Companies in the top quartile (top 25%) have a Altman Z-Score significantly above this median, while those in the bottom quartile fall well below. However, Altman Z-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Thyrocare Technologies's current Altman Z-Score of 33.28 is 1286.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Altman Z-Score mean?
A high Altman Z-Score can signal that a stock is expensive relative to its fundamentals. The Altman Z-score measures a company's bankruptcy risk. View historical data on Thyrocare Technologies and its competitors. For the Medical Diagnostics & Research industry, the median Altman Z-Score is 2.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Thyrocare Technologies's current Altman Z-Score is 33.28, which is 32% above median its own 10-year median of 25.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Thyrocare Technologies stock overvalued right now?
Based on GuruFocus' analysis, Thyrocare Technologies (NSE:THYROCARE) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹395.01, compared to a current price of ₹515.70 — trading 30.6% above its estimated fair value. The current Altman Z-Score is 33.28, which is 32% above median its 10-year median of 25.21 and 1286.7% above the Medical Diagnostics & Research industry median of 2.40. Thyrocare Technologies' overall GF Score™ is 87/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Altman Z-Score calculated?
Altman Z-Score is calculated from a company's financial statements. For Thyrocare Technologies (NSE:THYROCARE), the current Altman Z-Score is 33.28 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Thyrocare Technologies (NSE:THYROCARE) Overvalued in 2026?
Based on GuruFocus' analysis, Thyrocare Technologies stock appears to be overvalued.
The current stock price of ₹515.70 is trading 30.6% above its estimated GF Value™ of ₹395.01.
GuruFocus considers Thyrocare Technologies to be Significantly Overvalued.
Key valuation signals for NSE:THYROCARE:
Altman Z-Score: 33.28 (32% above median its 10-year median of 25.21)
GF Value™: ₹395.01 vs. price of ₹515.70 (30.6% above fair value)
Industry Position: 1286.7% above the Medical Diagnostics & Research median (#2 of 204)
No single metric tells the full story. See the NSE:THYROCARE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Thyrocare Technologies Ltd is a diagnostics & research company. The company has three business segments: Diagnostic Testing Services, Imaging Services, and Others: Sale of testing equipment and consumables. The Diagnostic Testing Services segment provides Diagnostic and testing services, selling of consumables used for the collection and promotion of the pathology segment. The company majorly earns the majority of its revenue from the Diagnostic Testing Services segment. The Imaging Services segment operates Diagnostic and imaging services, selling of radio-pharmaceuticals, and selling of consumables for reporting. The Other business segment is engaged in the selling of glucometers and glucostrips under the brand name Sugarscan. The company earns the vast majority of its revenue in India.
87GF Score
Get the complete analysis for NSE:THYROCARE
Altman Z-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:THYROCARE has been successfully added to your 
